Literature DB >> 12410576

Diagnosis of lupus anticoagulant in the lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature.

Vicente Baca1, Guadalupe Montiel, Luis Meillón, Javier Pizzuto, Teresa Catalán, Luis Juan-Shum, Beatriz Nieva.   

Abstract

We report a severe hemorrhagic disorder in two pediatric patients with lupus anticoagulant (LA) associated to acquired factor II (prothrombin) deficiency. In both patients, hemorrhagic symptoms resolved after corticosteroid therapy. Serial coagulation studies showed that Staclot LA assay was more sensitive than DVVconfirm and Staclot PNP tests to confirm the presence of LA when associated with severe factor II deficiency. Both patients had non-neutralizing anti-prothrombin antibodies and their titers inversely correlated with factor II activity (r = -1.0, P < 0.0001). Associated findings in these patients included positive immunologic tests for systemic lupus erythematosus, a positive anti-cardiolipin antibody, and anti-beta(2) GPI antibodies in one case. Our findings point out the difficulty in diagnosing LA associated with acquired factor II deficiency and suggest that, in confirmation of its phospholipid dependency, the inclusion of a source of normal human plasma in the test sequence to correct for any factor deficiency and a confirmatory step utilizing hexagonal (II) phase phospholipids may be crucial to the diagnosis of LA in some patients with LA-hypoprothrombinemia syndrome. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410576     DOI: 10.1002/ajh.10194

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.

Authors:  Tomoko Matsumoto; Keiji Nogami; Midori Shima
Journal:  Int J Hematol       Date:  2016-10-11       Impact factor: 2.490

2.  Pulmonary hemorrhage in pediatric lupus anticoagulant hypoprothrombinemia syndrome.

Authors:  Ji Soo Kim; Min Jae Kim; E Young Bae; Dae Chul Jeong
Journal:  Korean J Pediatr       Date:  2014-04-30

Review 3.  Laboratory diagnosis of the lupus anticoagulant.

Authors:  Thomas L Ortel
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 4.  Lupus anticoagulant-hypoprothrombinemia syndrome and immunoglobulin-A vasculitis: a report of Japanese sibling cases and review of the literature.

Authors:  Kaori Fujiwara; Junya Shimizu; Hirokazu Tsukahara; Akira Shimada
Journal:  Rheumatol Int       Date:  2019-08-07       Impact factor: 2.631

Review 5.  The challenge of bleeding in antiphospholipid antibody-positive patients.

Authors:  Giulia Pazzola; Stéphane Zuily; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

6.  Steady improvement of prothrombin levels after cyclophosphamide therapy in pediatric lupus anticoagulant hypoprothrombinemia syndrome (LAHPS).

Authors:  Andrea Taddio; AnneMarie C Brescia; Loredana Lepore; Carlos D Rose'
Journal:  Clin Rheumatol       Date:  2007-05-22       Impact factor: 2.980

Review 7.  Transient antiphospholipid antibodies associated with acute infections in children: a report of three cases and a review of the literature.

Authors:  H Mizumoto; T Maihara; E Hiejima; M Shiota; A Hata; S Seto; T Atsumi; T Koike; D Hata
Journal:  Eur J Pediatr       Date:  2006-03-22       Impact factor: 3.183

8.  Lupus anticoagulant hypoprothrombinemia syndrome associated with systemic lupus erythematosus in children: report of two cases and systematic review of the literature.

Authors:  Rakesh Kumar Pilania; Deepti Suri; Ankur Kumar Jindal; Narender Kumar; Avinash Sharma; Praveen Sharma; Sandesh Guleria; Amit Rawat; Jasmina Ahluwalia; Surjit Singh
Journal:  Rheumatol Int       Date:  2018-08-11       Impact factor: 3.580

9.  Acquired Factor V Inhibitor.

Authors:  Daisuke Hirai; Yugo Yamashita; Nobutoyo Masunaga; Toshiaki Katsura; Masaharu Akao; Yoshiaki Okuno; Hiroshi Koyama
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.